Spots Global Cancer Trial Database for Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

Official Title: Genetic Predictors of AML Treatment Response

Study ID: NCT01024127

Conditions

Adult Acute Myeloid Leukemia in Remission

Childhood Acute Myeloid Leukemia in Remission

Interventions

Laboratory Biomarker Analysis

Study Description

Brief Summary: This research trial studies deoxyribonucleic acid (DNA) in blood or bone marrow samples from younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.

Detailed Description: PRIMARY OBJECTIVES: l. Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML) relapse and infection risk. II. Validate positive associations seen in the genome-wide scan with a fine mapping approach. III. Perform simulated clinical trials using germline genetic variation data to test the feasibility of using genetic data to inform the clinical care of pediatric patients with AML. OUTLINE: Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.